Skip to content

Study · Animal study (in vivo) · rat · 2005

2 results

Effect of peptide Vilon on the content of transforming growth factor-beta and permeability of microvessels during experimental chronic renal failure.

Gavrisheva NA, Malinin VV, Ses TP, Kozlov KL, Panchenko AV, Titkov AY

Bulletin of experimental biology and medicine1 Jan 2005Cited by 1 (Europe PMC)

PMID16142267 (opens in a new tab)DOI10.1007/s10517-005-0202-9 (opens in a new tab)PepBankPUB-16142267
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats two months after chronic renal failure onset, subcutaneous Vilon significantly decreased serum transforming growth factor-beta(1).

    In plain wordsIn rats with early chronic renal failure, Vilon decreased a blood growth factor.

    Peptide
    Vilon (KE)
    Outcome
    DecreaseSerum transforming growth factor-beta(1)
    Study

    ratn: not reported in source

    Chronic renal failure, two months after onset
    Outcome group
    Inflammation markers · Kidney and urinary
    Studied dose
    Dose not stated · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    Subcutaneous injection of Vilon significantly decreased serum concentration of transforming growth factor-beta(1) and permeability of mesenteric microvessels in rats 2 months after the onset of chronic renal failure.
    1 context sentence
    Summary · context
    We studied the effect of Vilon in rats 2, 4, and 6 months after the onset of chronic renal failure.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats two months after chronic renal failure onset, subcutaneous Vilon significantly decreased mesenteric microvessel permeability.

    In plain wordsIn rats with early chronic renal failure, Vilon decreased leakage through small intestinal blood vessels.

    Peptide
    Vilon (KE)
    Outcome
    DecreaseMesenteric microvessel permeability
    Study

    ratn: not reported in source

    Chronic renal failure, two months after onset
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    Subcutaneous injection of Vilon significantly decreased serum concentration of transforming growth factor-beta(1) and permeability of mesenteric microvessels in rats 2 months after the onset of chronic renal failure.
    1 context sentence
    Summary · context
    We studied the effect of Vilon in rats 2, 4, and 6 months after the onset of chronic renal failure.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 17:05 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.